SHR6390 + placebo
Phase 3ActiveDevelopment Stage
Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer
Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer
Apr 30, 2021 → Oct 31, 2031
About SHR6390 + placebo
SHR6390 + placebo is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04842617. Target conditions include Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer.
What happened to similar drugs?
9 of 20 similar drugs in Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer were approved
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04842617 | Phase 3 | Active |
Competing Products
20 competing products in Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer